ARTICLE | Clinical News
CRL for Sandoz's biosimilar rituximab
May 4, 2018 4:24 PM UTC
The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) said it received a complete response letter from FDA for a BLA for GP2013, the company's biosimilar of Rituxan/MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY).
Sandoz said it is evaluating the letter...
BCIQ Target Profiles